Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence

Vascular Pharmacology

Volumn 73, Issue , 2015, Pages 1-3

  Fadini, Gian Paolo ^a,b   Albiero, Mattia ^a,b   Avogaro, Angelo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; BIOLOGICAL MARKER; DPP4 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; ENZYME INHIBITION; HEART FAILURE; HUMAN; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASCULARIZATION; ANIMAL; BLOOD; BLOOD VESSEL; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DRUG EFFECTS; ENZYMOLOGY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; BLOOD VESSELS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84941739763     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.004     Document Type: Review

References (35)

1. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
2. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
3. Fadini G.P., Albiero M., Menegazzo L., de Kreutzenberg S.V., Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes. Metab. 2012, 14:518-522.
4. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vasc. Pharmacol. 2011, 55:10-16.
5. Christopherson K.W., Hangoc G., Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 2002, 169:7000-7008.
6. Davis D.A., Singer K.E., De La Luz Sierra M., Narazaki M., Yang F., Fales H.M., Yarchoan R., Tosato G. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 2005, 105:4561-4568.
7. Duke-Cohan J.S., Morimoto C., Rocker J.A., Schlossman S.F. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J. Biol. Chem. 1995, 270:14107-14114.
8. Poncina N., Albiero M., Menegazzo L., Cappellari R., Avogaro A., Fadini G.P. The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. Cardiovasc. Diabetol. 2014, 13:92.
9. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M., Eckardt K., Kaufman J.M., Ryden M., Muller S., Hanisch F.G., Ruige J., Arner P., Sell H., Eckel J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60:1917-1925.
10. Ussher J.R., Drucker D.J. Cardiovascular actions of incretin-based therapies. Circ. Res. 2014, 114:1788-1803.
11. Shah Z., Pineda C., Kampfrath T., Maiseyeu A., Ying Z., Racoma I., Deiuliis J., Xu X., Sun Q., Moffatt-Bruce S., Villamena F., Rajagopalan S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc. Pharmacol. 2011, 55:2-9.
12. Choi S., Park S., Oh C., Leem J., Park K., IK L. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NFE2-related factor 2 activation. Vasc. Pharmacol. 2015.
13. Dai Y., Dai D., Wang X., Ding Z., Mehta J.L. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc. Drugs Ther. 2014, 28:425-432.
14. Fadini G.P., Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 2013, 229:23-29.
15. Iqbal N., Parker A., Frederich R., Donovan M., Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc. Diabetol. 2014, 13:33.
16. Engel S.S., Golm G.T., Shapiro D., Davies M.J., Kaufman K.D., Goldstein B.J. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc. Diabetol. 2013, 12:3.
17. Goossen K., Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes. Metab. 2012, 14:1061-1072.
18. Johansen O.E., Neubacher D., von Eynatten M., Patel S., Woerle H.J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc. Diabetol. 2012, 11:3.
19. Schweizer A., Dejager S., Foley J.E., Couturier A., Ligueros-Saylan M., Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes. Metab. 2010, 12:485-494.
20. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013, 369:1317-1326.
21. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.T., Fleck P.R., Mehta C.R., Kupfer S., Wilson C., Cushman W.C., Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013, 369:1327-1335.
22. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., Josse R., Kaufman K.D., Koglin J., Korn S., Lachin J.M., McGuire D.K., Pencina M.J., Standl E., Stein P.P., Suryawanshi S., Van de Werf F., Peterson E.D., Holman R.R. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015, 373:232-242.
23. Scirica B.M., Braunwald E., Raz I., Cavender M.A., Morrow D.A., Jarolim P., Udell J.A., Mosenzon O., Im K., Umez-Eronini A.A., Pollack P.S., Hirshberg B., Frederich R., Lewis B.S., McGuire D.K., Davidson J., Steg P.G., Bhatt D.L. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014, 130:1579-1588.
24. Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., Whincup P.H., Mukamal K.J., Gillum R.F., Holme I., Njolstad I., Fletcher A., Nilsson P., Lewington S., Collins R., Gudnason V., Thompson S.G., Sattar N., Selvin E., Hu F.B., Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011, 364:829-841.
25. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359:1577-1589.
26. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., Howard B.V., Kirkman M.S., Kosiborod M., Reaven P., Sherwin R.S. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187-192.
27. Avogaro A., Fadini G.P. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014, 37:2884-2894.
28. Fadini G.P., Boscaro E., Albiero M., Menegazzo L., Frison V., de Kreutzenberg S., Agostini C., Tiengo A., Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609.
29. Rigato M., Bittante C., Albiero M., Avogaro A., Fadini G.P. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2015, 100:2666-2672.
30. Cheung N., Wang J.J., Klein R., Couper D.J., Sharrett A.R., Wong T.Y. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007, 30:1742-1746.
31. Gerstein H.C., Werstuck G.H. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diab. Endocrinol. 2013, 1:71-78.
32. Juutilainen A., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007, 30:292-299.
33. Rosenson R.S., Fioretto P., Dodson P.M. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis 2011, 218:13-18.
34. Devin J.K., Pretorius M., Nian H., Yu C., Billings FTt, Brown N.J. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension 2014, 63:951-957.
35. Fadini G.P., Avogaro A., Degli Esposti L., Russo P., Saragoni S., Buda S., Rosano G., Pecorelli S., Pani L. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur. Heart J. 2015.